64 completed, 23 recruiting, 23 unknown, 19 terminated. 151 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 151 | Completed 64, Recruiting 23, Unknown 23, Terminated 19, Withdrawn 9, Not yet recruiting 6, Active not recruiting 4, Enrolling by invitation 3 |
Follow Crohn Disease: new trials by email Literature Review of Crohn Disease trials Research Report on Crohn Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 50 | 2026-12-01 | 2026-08-24 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-23 |
| Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® TyboWe® Adalimumab Injection - Crohn's Disease | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 50 | 2026-09-23 | 2026-09-24 |
| INSIGHT-IBD Pragmatic Study Mirikizumab, Anti-TNF agents, anti-integrin antibodies - Ulcerative Colitis (UC), Crohn Disease (CD) | Phase 4 | Enrolling by invitation | Specialty Networks Research. | 400 | 2026-08-12 | 2026-10-29 |
| A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative | Phase 4 | Recruiting | Janssen Research & Development, LLC | 10 | 2026-08-07 | 2026-11-03 |
| Stopping PPI Therapy in Inactive IBD Continue PPI Therapy, Withdraw PPI Therapy - Ulcerative Colitis (UC), Crohn's Disease | Phase 4 | Recruiting | University of Nottingham | 80 | 2026-07-01 | 2026-07-08 |
| Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study Guselkumab - Crohn Disease (CD), Intensification | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 210 | 2026-06-18 | 2026-06-30 |
| Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease Mirikizumab - IV, Mirikizumab - SC - Crohn Disease (CD) | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 75 | 2026-05-11 | 2026-11-04 |
| Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD Mirikizumab - Crohn Disease | Phase 4 | Recruiting | Alimentiv Inc. | 60 | 2026-04-20 | 2026-10-26 |
| Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease Infliximab, Akkermansia muciniphila + Infliximab - Crohn's Diseases | Phase 4 | Not yet recruiting | Chinese Medical Association | 400 | 2026-04-01 | 2026-02-17 |
| Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease Palmitoleic Acid + Infliximab, Infliximab - Crohn's Disease | Phase 4 | Not yet recruiting | Chinese Medical Association | 400 | 2026-04-01 | 2026-02-18 |
| TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification - Crohn Disease (CD) | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 312 | 2026-03-01 | 2026-06-09 |
| MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease PK-model to decide when to dose Vedolizumab and Ustekinumab - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Enrolling by invitation | Odense University Hospital | 166 | 2026-01-23 | 2026-11-06 |
| A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) Guselkumab (GUS) - Crohn Disease | Phase 4 | Recruiting | Xian-Janssen Pharmaceutical Ltd. | 78 | 2025-12-30 | 2026-11-03 |
| Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety Interleukin 23 - Crohn's Disease and Ulcerative Colitis | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 200 | 2025-12-01 | 2026-04-24 |
| De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis Ustekinumab 90 mg SC q8w, Ustekinumab 90 mg SC q12w - Crohn Disease (CD), Ulcerative Colitis (UC) | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 115 | 2025-10-08 | 2025-12-26 |
| Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis Mirikizumab - Crohn Disease (CD), Crohns Disease | Phase 4 | Not yet recruiting | Rubix LS | 150 | 2025-07-16 | 2025-07-10 |
| A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease | Phase 4 | Recruiting | Takeda | 200 | 2025-03-27 | 2026-10-28 |
| Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients Tirzepatide, Mediterranean diet - Crohn Disease | Phase 4 | Active not recruiting | University of Miami | 24 | 2025-03-05 | 2026-10-29 |
Showing 20 of 151. Sign in to see all of them.
Colitis, Ulcerative (43) · Inflammatory Bowel Diseases (36) · Vitamin D Deficiency (4) · Arthritis, Psoriatic (3) · Arthritis, Rheumatoid (3) · Bone Diseases, Metabolic (3) · Intestinal Diseases (3) · Iron Deficiencies (3) · Anemia, Iron-Deficiency (2) · Breast Feeding (2) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Psoriasis (2) · Recurrence (2)
Gastroenteritis (150) · Digestive System Diseases (149) · Gastrointestinal Diseases (149) · Intestinal Diseases (148) · Inflammatory Bowel Diseases (115) · Colonic Diseases (44) · Colitis (43) · Nutritional and Metabolic Diseases (12) · Metabolic Diseases (9) · Musculoskeletal Diseases (9) · Pathological Conditions, Signs and Symptoms (9) · Bone Diseases (8) · Pathologic Processes (6) · Arthritis (5) · Immune System Diseases (5)
Infliximab (28) · Adalimumab (20) · vedolizumab (16) · Azathioprine (9) · Ustekinumab (9) · Methotrexate (7) · Cholecalciferol (5) · Vitamin D (5) · CT-P13 (4) · Mercaptopurine (4) · Prednisone (4) · mirikizumab (4) · Adrenal Cortex Hormones (3) · Certolizumab Pegol (3) · guselkumab (3)
Takeda (10) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (9) · Sixth Affiliated Hospital, Sun Yat-sen University (5) · Alimentiv Inc. (4) · Asan Medical Center (3) · Erasmus Medical Center (3) · Mayo Clinic (3) · Prof. Arie Levine (3) · AbbVie (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW (2) · Biogen (2) · Cedars-Sinai Medical Center (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Children's Hospital of Fudan University (2)
United States (41) · Canada (21) · France (16) · Netherlands (14) · China (12) · Israel (10) · Belgium (9) · United Kingdom (9) · Italy (7) · Denmark (6) · Spain (6) · Australia (5) · South Korea (5) · Czechia (4) · Germany (4)
Arie Levine, MD (3) · Brian G Feagan, MD (2) · Dan Turner, MD, PhD (2) · David Laharie (2) · Maria O'Sullivan, PhD (2) · Michal Kori, MD (2) · Parakkal Deepak, MBBS, MS (2) · Raanan Shamir, MD (2) · Ron Shaoul, MD (2) · Vipul Jairath, MD (2)
PMID 40357993, PMID 10896917, PMID 12432298, PMID 14762782, PMID 1499440, PMID 15058524, PMID 15168373, PMID 16116317, PMID 16279893, PMID 16393226, PMID 16393228, PMID 16500392, PMID 16611269, PMID 1669678, PMID 17058158, PMID 17058159, PMID 17308939, PMID 17593171, PMID 17762967, PMID 18295023, PMID 18564124, PMID 19109962, PMID 1948581, PMID 2179031, PMID 23644079, PMID 23878167, PMID 24284413, PMID 24423431, PMID 24572205, PMID 24953836, PMID 25524543, PMID 25576753, PMID 25705682, PMID 26137304, PMID 26245216, PMID 26275480, PMID 26342731, PMID 2668130, PMID 26765407, PMID 26848182, PMID 27932449, PMID 28090335, PMID 28502609, PMID 29420227, PMID 30649836, PMID 30762274, PMID 30891808, PMID 31194979, PMID 31290715, PMID 31793630
2014 (4), 2016 (3), 2025 (2), 2009 (1), 2015 (1), 2017 (1), 2023 (1), R01DK125495 (1), U01DK134356 (1)